ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 147 filers reported holding ASCENDIS PHARMA A/S in Q4 2019. The put-call ratio across all filers is 0.23 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $215,840 | +4.4% | 2,305 | -0.5% | 0.14% | -4.9% |
| Q2 2023 | $206,792 | -17.0% | 2,317 | -0.3% | 0.14% | -44.4% |
| Q1 2023 | $249,287 | +89571.6% | 2,325 | +2.2% | 0.26% | +30.8% |
| Q4 2022 | $278 | -99.9% | 2,276 | -0.1% | 0.20% | 0.0% |
| Q3 2022 | $235,000 | +10.8% | 2,278 | +0.0% | 0.20% | +23.0% |
| Q2 2022 | $212,000 | -20.9% | 2,277 | -0.3% | 0.16% | +4.5% |
| Q1 2022 | $268,000 | -8.8% | 2,284 | +4.6% | 0.15% | +12.4% |
| Q4 2021 | $294,000 | -15.5% | 2,183 | -0.0% | 0.14% | +8.7% |
| Q3 2021 | $348,000 | +7.1% | 2,184 | -11.6% | 0.13% | +16.7% |
| Q2 2021 | $325,000 | +8.3% | 2,471 | +6.0% | 0.11% | -41.9% |
| Q1 2021 | $300,000 | -48.9% | 2,331 | -33.8% | 0.19% | -91.6% |
| Q4 2020 | $587,000 | +6.1% | 3,519 | -1.8% | 2.21% | +630.8% |
| Q3 2020 | $553,000 | +1.7% | 3,584 | -2.5% | 0.30% | -6.2% |
| Q2 2020 | $544,000 | +31.4% | 3,675 | 0.0% | 0.32% | +79.9% |
| Q1 2020 | $414,000 | -12.7% | 3,675 | +7.9% | 0.18% | +6.5% |
| Q4 2019 | $474,000 | +46.3% | 3,405 | +1.3% | 0.17% | -6.1% |
| Q3 2019 | $324,000 | -5.5% | 3,360 | +12.7% | 0.18% | +32.6% |
| Q2 2019 | $343,000 | – | 2,981 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |